Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

While anti-CD47 antibodies hold promise for cancer immunotherapy, early-phase clinical
trials have shown limited clinical benefit, suggesting that CD47 blockade alone might be …

Simple Summary The combination of disulfiram and copper is a novel anti-cancer drug
under clinical development for the treatment of several tumor types including hepatocellular …

Immune checkpoint blockade is a compelling approach in tumor immunotherapy. Blocking
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …

Simple Summary Macrophages are the “big eaters” of the immune system who are in charge
of engulfing undesirable substances. Macrophages are vital for the human body as they are …

Although immunotherapy is relatively effective in treating hematological malignancies, their
efficacy against solid tumors is still suboptimal or even noneffective presently. Compared to …

Metastasis causes greater than 90% of cancer-associated deaths, presenting huge
challenges for detection and efficient treatment of cancer due to its high heterogeneity and …

Macrophages, as one of the most abundant tumor-infiltrating cells, play an important role in
tumor development and metastasis. The frequency and polarization of tumor-associated …

Modulating the immune system to treat diseases, including myeloid malignancies, has
resulted in the development of a multitude of novel therapeutics in recent years …